Siponimod: a new view at the therapy of secondary progressive multiple sclerosis
Volume: 121, Issue: 7, Pages: 124 - 124
Published: Jan 1, 2021
Abstract
Siponimod is a selective modulator of sphingosine-1-phosphate (S1P) receptors of types 1 and 5, registered in the Russian Federation for the treatment of patients with secondary progressive multiple sclerosis (SPMS), regardless of the presence or absence of exacerbations. The effectiveness of the drug in comparison with placebo was demonstrated in patients with SPMS in the international clinical trial EXPAND (phase III). This review devotes...
Paper Details
Title
Siponimod: a new view at the therapy of secondary progressive multiple sclerosis
Published Date
Jan 1, 2021
Volume
121
Issue
7
Pages
124 - 124
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History